Related to Geron Sidelines Stem Cell Programs and Cuts Workforce to Focus on Clinical Cancer Candidates

• Benefits of Osiris’ Mesenchymal Stem Cell Therapy Confirmed in Late-Stage Studies against SR-GvHD
  
• T2cure’s Mid-Stage Somatic Stem Cell Product Receives EMEA Quality Certification
  
• BioTime Sets Up OrthoCyte Subsidiary for Stem Cell Based Orthopedic Products
  
• CIRM Commits $25M to Overcome Immune Rejection of Stem Cell Therapies
  
• Scientists Enable Nerve Regeneration after Spinal Cord Injury in Rodents
  
• California Institute for Regenerative Medicine Bankrolls 12 Grants with $243M
  
• URMC Gets $15M to Study Homspera as a Radiation-Induced Injury Countermeasure
  
• Geron to Develop Human ESC-Derived Chondrocytes for Cartilage Repair
  
• CIRM to Dole Out $72M to Advance Research and Recruit Stem Cell Scientist
  
• First Patient Receives ReNeuron’s Neural Stem Cell Therapy
  
• InVivo Secures $13M In Advance of Clinical Program for Spinal Cord Injury Product
  
• Cephalon Shells Out $350M to Commercialize Mesoblast Stem Cell Therapies
  
• ACT Secures $25M and FDA Approval to Start Clinical Trials of ESC-Derived Therapy
  
• BioTime Buys Assets from Cell Targeting to Boost Its Regenerative Medicine Focus
  
• Researchers Find Extended Culturing of Engineered iPSCs Doesn’t Increase Mutations
  
• Plasticell Spins Out Progenitor Labs for Regenerative Drug Discovery
  
• InVivo and Miami Project to Combine Bioscaffolds with Schwann Cells for Spinal Cord Injury
  
• U.S. Army Institute of Surgical Research Taps Arteriocyte for Orthopedic Trauma Cellular Therapies
  
• Acorda Licenses Phase II-Ready Brain and Spinal Cord Injury Candidate from Medtronic
  
• ACT Gets U.K. Go-Ahead to Start First Ever Non-U.S. Trial with hESC-Derived Cell Therapy